EP. 1: The Evolving Landscape of Newly Diagnosed Multiple Myeloma
A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.
EP. 2: Highlights from ASH 2023 in Transplant-Eligible NDMM
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
EP. 3: Advances in the Treatment of High-Risk MM
Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.
EP. 4: Role of Transplant and MRD in Newly Diagnosed MM
Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.
EP. 5: The Evolving Treatment Paradigm for Transplant Ineligible MM
The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.
EP. 6: Treatment of Multiple Myeloma at Early Relapse
A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.
EP. 7: Potential Role for CAR T-Cell Therapy in MM at Early Relapse
Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.
EP. 8: Updates on BCMA-Targeting Bispecifics in MM
An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.
EP. 9: Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma
Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.
EP. 10: Step-Up Dosing Practices for Bispecifics in Multiple Myeloma
Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.
EP. 11: Adverse Effects Related to Bispecifics in Multiple Myeloma
Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
EP. 12: GPRC5D-Targeting Bispecifics in Multiple Myeloma
The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
EP. 13: CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
EP. 14: Treatment Considerations and Sequencing in Multiple Myeloma
The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
